STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNN
  4. [Form 4] Imunon, Inc. Insider Trading Activity

Imunon, Inc. (IMNN) general counsel grants and sells 2,541 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., received a grant of 2,541 shares of common stock on July 31, 2026 in lieu of a portion of base salary at $1.59 per share, then sold 2,541 shares on August 3, 2026 at a weighted average of $1.5651 per share, within a $1.56-$1.575 range.

Positive

  • None.

Negative

  • None.
Insider Eylward Susan
Role General Counsel and Corp Sec
Sold 2,541 shs ($4K)
Type Security Shares Price Value
Sale Common Stock F2 2,541 $1.5651 $4K
Grant/Award Common Stock F1 2,541 $1.59 $4K
Holdings After Transaction: Common Stock — 2,896 shares (Direct)
Footnotes (2)
  1. F1. Stock granted in lieu of cash for portion of base salary
  2. F2. Reflects a weighted average sale price of $1.5651 per share, at prices ranging from $1.56 to $1.575 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.
Shares granted 2,541 shares Common Stock granted on July 31, 2026 in lieu of portion of base salary
Grant price $1.59 per share Price for stock granted on July 31, 2026
Shares sold 2,541 shares Common Stock sold on August 3, 2026
Weighted average sale price $1.5651 per share Weighted average for August 3, 2026 sale transactions
Sale price range $1.56-$1.575 per share Range of prices for August 3, 2026 sale transactions
weighted average sale price financial
"Reflects a <b>weighted average sale price</b> of $1.5651 per share"
in lieu of cash financial
"Stock granted <b>in lieu of cash</b> for portion of base salary"
base salary financial
"Stock granted in lieu of cash for portion of <b>base salary</b>"
sale in open market or private transaction financial
"Transaction code description: <b>Sale in open market or private transaction</b>"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Imunon (IMNN) report for Susan Eylward?
Susan Eylward received 2,541 Imunon common shares on July 31, 2026 as stock in lieu of a portion of base salary at $1.59 per share, then sold 2,541 shares on August 3, 2026 at a weighted average price of $1.5651 per share.

Was the Imunon (IMNN) stock grant to Susan Eylward part of her cash compensation?
Yes. The filing states the 2,541-share grant was "Stock granted in lieu of cash for portion of base salary," meaning part of Susan Eylward’s base salary was paid in Imunon common stock instead of cash at $1.59 per share.

At what prices did Susan Eylward sell Imunon (IMNN) shares on August 3, 2026?
The sale reflects a weighted average price of $1.5651 per share, with individual trades executed at prices ranging from $1.56 to $1.575 per share, as disclosed in the footnote describing the open market or private transaction.

How many Imunon (IMNN) shares did Susan Eylward sell versus receive?
Susan Eylward received 2,541 Imunon common shares as a stock grant tied to base salary, and sold 2,541 Imunon common shares in a separate transaction days later, resulting in a reported sequence of one acquisition and one sale of the same share amount.

Were Susan Eylward’s Imunon (IMNN) transactions reported as open market trades?
The acquisition was reported as a grant or award in lieu of cash salary, while the disposition used a code described as a sale in open market or private transaction, with a disclosed weighted average sale price and detailed price range information.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Eylward Susan
(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100
(Street)
LAWRENCEVILLE NEW JERSEY 08648
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel and Corp Sec
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/31/2026A2,541(1)A$1.595,437D
Common Stock08/03/2026S2,541D$1.5651(2)2,896D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for portion of base salary
2. Reflects a weighted average sale price of $1.5651 per share, at prices ranging from $1.56 to $1.575 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.
/s/ Susan Eylward08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR